T2D Study Guide, October: SGLT2 Inhibitors, GLP-1 Agonists, CV Outcomes


At-a-glance: SGLT2 inhibitors, GLP-1 agonists, insulin vs insulin, and more-a look at what’s new, what’s next.

Click through the slides above for our monthly at-a-glance reviews of recent studies in T2DM. Among our October topics:
• CV and renal outcomes with SGLT2 inhibitors
• Insulins go head to head
• Add-on options for metforminSee the slide legends for links to article summaries.

Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
© 2024 MJH Life Sciences

All rights reserved.